Canaccord raised the firm’s price target on Smith & Nephew to $35 from $34 and keeps a Hold rating on the shares. The firm said they delivered a solid quarter, coming in ahead of consensus expectations with underlying growth of +6%, including improvement in US knee performance vs the Q3 supported by the LEGION MS launch.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNN:
- Smith & Nephew: Building Momentum Toward FY26 Targets With New Products and Orthopaedics Driving Upside
- Smith & Nephew price target raised to 1,305 GBp from 1,290 GBp at Barclays
- Smith & Nephew Earnings Call Highlights Profitable Momentum
- Smith & Nephew Updates Voting Share Capital and Rights as of 28 February 2026
- Smith+Nephew Posts Strong 2025 Results, Completes Transformation and Sets 2026 Growth Targets